Does Terlipressin Improve Renal Outcome After Liver Surgery (TIROL)
Does Terlipressin Improve Renal Outcome After Liver Surgery - A Double-Blinded Randomized Control Trial (TIROL-Trial)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Zurich, Switzerland, 8091
- Department of Visceral and Transplantation Surgery of the University Hospital of Zurich
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- >=12% risk for post-operative ARF on our recently developed and validated prediction score for ARF after liver surgery, patients will need five points or more in the pre-operative assessment of the predictors to be enrolled in the trial
Exclusion Criteria:
- < 18 years
- liver cirrhosis
- coronary insufficiency with ST-elevation or ST-depression in the - - intra-operative ECG as signs of an acute coronary syndrome
- pregnancy and breast feed
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: Control Group
Patients receiving post-operative placebo (Ringer lactate solution) treatment to preserve the renal function
|
Patients are receiving a post-operative intravenous Ringer's lactate solution
Other Names:
|
|
Experimental: Terlipressin Group
Patients receiving a post-operative intravenous terlipressin treatment in association with human albumin to preserve the renal function
|
Patients are receiving a post-operative intravenous terlipressin treatment in association with human albumin to preserve the renal function
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
serum creatinine peak level within 48 hours post-operative
Time Frame: within 48 hours post-operative
|
within 48 hours post-operative
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
the urinary output/24h
Time Frame: Post Operative Day 0 to 3
|
Post Operative Day 0 to 3
|
|
|
Need for hemofiltration and/or hemodialysis
Time Frame: Post Operative Day 0 - 14
|
participants will be followed for the duration of hospital stay, an expected average of 14 days
|
Post Operative Day 0 - 14
|
|
Morbidity & mortality
Time Frame: Post Operative Day 0 - 14
|
measured by the comprehensive complication index; participants will be followed for the duration of hospital stay, an expected average of 14 days
|
Post Operative Day 0 - 14
|
|
Liver function
Time Frame: Post Operative Day 0 - 5
|
assessed by serum levels of aspartate aminotransferase (AST) and alanine aminotransferase (ALT)
|
Post Operative Day 0 - 5
|
|
length of hospital stay
Time Frame: Post Operative Day 0 - 14
|
in days; participants will be followed for the duration of hospital stay, an expected average of 14 days
|
Post Operative Day 0 - 14
|
|
length of ICU stay
Time Frame: Post Operative Day 0 - 7
|
in days; participants will be followed for the duration of ICU stay, an expected average of 7 days
|
Post Operative Day 0 - 7
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Pierre-Alain Clavien, MD PhD, Departement of Visceral and Transplantation Surgery Zurich
Study record dates
Study Major Dates
Study Start (Anticipated)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2012-0581
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.